View ValuationShoulder Innovations 향후 성장Future 기준 점검 2/6Shoulder Innovations은 연간 수입과 매출이 각각 21%와 24% 증가할 것으로 예상되고 EPS는 연간 36.2%만큼 증가할 것으로 예상됩니다.핵심 정보21.0%이익 성장률36.20%EPS 성장률Medical Equipment 이익 성장13.3%매출 성장률24.0%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트15 Jul 2026최근 향후 성장 업데이트공고 • May 15Shoulder Innovations, Inc. Increases Revenue Guidance for the Full Year 2026Shoulder Innovations, Inc. increased revenue guidance for the full year 2026. The company expected net revenue for the full year 2026 to be in the range of $65 million to $68 million, representing growth of approximately 37% to 44% over full year 2025 net revenue. This compares to prior guidance of $62 million to $65 million, representing growth of approximately 31% to 37% over full year 2025 net revenue.공고 • Mar 11Shoulder Innovations, Inc. Provides Earnings Guidance for the Full Year 2026Shoulder Innovations, Inc. provided earnings guidance for the full year 2026. For the year, the company expects net revenue for the full year 2026 to be in the range of $62 million to $65 million, representing growth of approximately 31% to 37% over full year 2025 net revenue.모든 업데이트 보기Recent updates공고 • Jul 15Shoulder Innovations, Inc. to Report Q2, 2026 Results on Aug 06, 2026Shoulder Innovations, Inc. announced that they will report Q2, 2026 results After-Market on Aug 06, 2026공고 • May 15Shoulder Innovations, Inc. Increases Revenue Guidance for the Full Year 2026Shoulder Innovations, Inc. increased revenue guidance for the full year 2026. The company expected net revenue for the full year 2026 to be in the range of $65 million to $68 million, representing growth of approximately 37% to 44% over full year 2025 net revenue. This compares to prior guidance of $62 million to $65 million, representing growth of approximately 31% to 37% over full year 2025 net revenue.공고 • May 01Shoulder Innovations, Inc., Annual General Meeting, Jun 26, 2026Shoulder Innovations, Inc., Annual General Meeting, Jun 26, 2026.공고 • Apr 28Shoulder Innovations Initiates Full Commercial Launch Of The Inset I-135rfx Humeral StemShoulder Innovations, Inc. (Shoulder Innovations, or the Company) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, announced full commercial launch of the InSet I-135RFX Humeral Stem ("InSet I-135RFX"). The commencement of full launch follows a successful limited market release and receipt of additional FDA 510(k) clearance for an expanded set of fracture indications, enabling the InSet I-135RFX to now be utilized in all primary, revision, and fracture total shoulder arthroplasty procedures. The InSet I-135RFX joins the smaller form factor InSet 95 and InSet 70, launched in 2024 and 2025, respectively, as the third addition to the I-Series humeral stem product line. Consistent with these earlier products, the InSet I-135RFX is built on Shoulder Innovations' exclusive InSet lateral-lateral implant philosophy, which has been shown in independent, peer reviewed research to reduce complications and maximize post-operative range of motion. To date, surgeons have utilized the InSet I-135RFX in both anatomic and reverse shoulder arthroplasty configurations and specifically value its ease of use, straightforward surgical technique, and seamless integration with Shoulder Innovations' two-tray surgical instrumentation system.공고 • Apr 23Shoulder Innovations, Inc. to Report Q1, 2026 Results on May 13, 2026Shoulder Innovations, Inc. announced that they will report Q1, 2026 results After-Market on May 13, 2026공고 • Mar 11Shoulder Innovations, Inc. Provides Earnings Guidance for the Full Year 2026Shoulder Innovations, Inc. provided earnings guidance for the full year 2026. For the year, the company expects net revenue for the full year 2026 to be in the range of $62 million to $65 million, representing growth of approximately 31% to 37% over full year 2025 net revenue.공고 • Mar 03Shoulder Innovations, Inc. Announces Board ChangesShoulder Innovations, Inc. announced the appointment of Drew Hykes to the company's Board of Directors and as a member of the Compensation Committee, effective February 26, 2026. Concurrent with Mr. Hykes's appointment, Geoff Pardo will resign as an Independent Director from the Board. Mr. Hykes is a seasoned medical device executive with more than 25 years of operating experience. He currently serves as President and Chief Executive Officer of Okami Medical, a privately held medical technology company pioneering novel vascular embolization solutions. He joined Okami Medical following nearly 8 years at Inari Medical, having served most recently as Chief Executive Officer from 2023 until Inari's acquisition by Stryker Corporation in 2025. He also held the roles of Chief Operating Officer and Chief Commercial Officer during his tenure at Inari Medical. Prior, he served as Vice President of Commercial Operations at Sequent Medical, where he led the commercialization strategy for the WEB Aneurysm Embolization system from early prototype to broad adoption in the European market, before Sequent's acquisition by Terumo Corporation. Earlier in his career, Mr. Hykes spent 11 years at Medtronic where he held multiple roles of increasing responsibility across various business units, including Vice President of Clinical and Regulatory Affairs, Vice President of Marketing, and Director of Investor Relations.공고 • Feb 13Shoulder Innovations, Inc. to Report Q4, 2025 Results on Mar 10, 2026Shoulder Innovations, Inc. announced that they will report Q4, 2025 results After-Market on Mar 10, 2026이익 및 매출 성장 예측DB:VB3 - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/2028105-24-15-9312/31/202786-29-25-21312/31/202667-36-41-3633/31/202654-44-44-34N/A12/31/202547-40-36-29N/A9/30/202542-36-29-23N/A6/30/202537-32-24-19N/A3/31/202535-17-21-17N/A12/31/202432-16-18-14N/A12/31/202319-13-16-13N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: VB3 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 vs 시장: VB3 향후 3년 동안 수익성이 없을 것으로 예상됩니다.고성장 수익: VB3 향후 3년 동안 수익성이 없을 것으로 예상됩니다.수익 대 시장: VB3 의 수익(연간 24%)이 German 시장(연간 6.6%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: VB3 의 수익(연간 24%)은 연간 20%보다 빠르게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: VB3의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/23 00:31종가2026/07/23 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Shoulder Innovations, Inc.는 5명의 분석가가 다루고 있습니다. 이 중 3명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Michael GormanBTIGDavid RomanGoldman SachsMatthew TaylorJefferies LLC2명의 분석가 더 보기
공고 • May 15Shoulder Innovations, Inc. Increases Revenue Guidance for the Full Year 2026Shoulder Innovations, Inc. increased revenue guidance for the full year 2026. The company expected net revenue for the full year 2026 to be in the range of $65 million to $68 million, representing growth of approximately 37% to 44% over full year 2025 net revenue. This compares to prior guidance of $62 million to $65 million, representing growth of approximately 31% to 37% over full year 2025 net revenue.
공고 • Mar 11Shoulder Innovations, Inc. Provides Earnings Guidance for the Full Year 2026Shoulder Innovations, Inc. provided earnings guidance for the full year 2026. For the year, the company expects net revenue for the full year 2026 to be in the range of $62 million to $65 million, representing growth of approximately 31% to 37% over full year 2025 net revenue.
공고 • Jul 15Shoulder Innovations, Inc. to Report Q2, 2026 Results on Aug 06, 2026Shoulder Innovations, Inc. announced that they will report Q2, 2026 results After-Market on Aug 06, 2026
공고 • May 15Shoulder Innovations, Inc. Increases Revenue Guidance for the Full Year 2026Shoulder Innovations, Inc. increased revenue guidance for the full year 2026. The company expected net revenue for the full year 2026 to be in the range of $65 million to $68 million, representing growth of approximately 37% to 44% over full year 2025 net revenue. This compares to prior guidance of $62 million to $65 million, representing growth of approximately 31% to 37% over full year 2025 net revenue.
공고 • May 01Shoulder Innovations, Inc., Annual General Meeting, Jun 26, 2026Shoulder Innovations, Inc., Annual General Meeting, Jun 26, 2026.
공고 • Apr 28Shoulder Innovations Initiates Full Commercial Launch Of The Inset I-135rfx Humeral StemShoulder Innovations, Inc. (Shoulder Innovations, or the Company) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, announced full commercial launch of the InSet I-135RFX Humeral Stem ("InSet I-135RFX"). The commencement of full launch follows a successful limited market release and receipt of additional FDA 510(k) clearance for an expanded set of fracture indications, enabling the InSet I-135RFX to now be utilized in all primary, revision, and fracture total shoulder arthroplasty procedures. The InSet I-135RFX joins the smaller form factor InSet 95 and InSet 70, launched in 2024 and 2025, respectively, as the third addition to the I-Series humeral stem product line. Consistent with these earlier products, the InSet I-135RFX is built on Shoulder Innovations' exclusive InSet lateral-lateral implant philosophy, which has been shown in independent, peer reviewed research to reduce complications and maximize post-operative range of motion. To date, surgeons have utilized the InSet I-135RFX in both anatomic and reverse shoulder arthroplasty configurations and specifically value its ease of use, straightforward surgical technique, and seamless integration with Shoulder Innovations' two-tray surgical instrumentation system.
공고 • Apr 23Shoulder Innovations, Inc. to Report Q1, 2026 Results on May 13, 2026Shoulder Innovations, Inc. announced that they will report Q1, 2026 results After-Market on May 13, 2026
공고 • Mar 11Shoulder Innovations, Inc. Provides Earnings Guidance for the Full Year 2026Shoulder Innovations, Inc. provided earnings guidance for the full year 2026. For the year, the company expects net revenue for the full year 2026 to be in the range of $62 million to $65 million, representing growth of approximately 31% to 37% over full year 2025 net revenue.
공고 • Mar 03Shoulder Innovations, Inc. Announces Board ChangesShoulder Innovations, Inc. announced the appointment of Drew Hykes to the company's Board of Directors and as a member of the Compensation Committee, effective February 26, 2026. Concurrent with Mr. Hykes's appointment, Geoff Pardo will resign as an Independent Director from the Board. Mr. Hykes is a seasoned medical device executive with more than 25 years of operating experience. He currently serves as President and Chief Executive Officer of Okami Medical, a privately held medical technology company pioneering novel vascular embolization solutions. He joined Okami Medical following nearly 8 years at Inari Medical, having served most recently as Chief Executive Officer from 2023 until Inari's acquisition by Stryker Corporation in 2025. He also held the roles of Chief Operating Officer and Chief Commercial Officer during his tenure at Inari Medical. Prior, he served as Vice President of Commercial Operations at Sequent Medical, where he led the commercialization strategy for the WEB Aneurysm Embolization system from early prototype to broad adoption in the European market, before Sequent's acquisition by Terumo Corporation. Earlier in his career, Mr. Hykes spent 11 years at Medtronic where he held multiple roles of increasing responsibility across various business units, including Vice President of Clinical and Regulatory Affairs, Vice President of Marketing, and Director of Investor Relations.
공고 • Feb 13Shoulder Innovations, Inc. to Report Q4, 2025 Results on Mar 10, 2026Shoulder Innovations, Inc. announced that they will report Q4, 2025 results After-Market on Mar 10, 2026